• Carfilzomib (PR-171): Translational Proteostasis

  2026-08-28

  Carfilzomib (PR-171) offers translational researchers a precise way to interrogate proteasome dependency, proteotoxic stress, and apoptosis in cancer models. This article connects its irreversible target engagement with combination strategies involving protein disulfide isomerase and histone deacetylase inhibition, while distinguishing established evidence from forward-looking experimental opportunities.

• Amplex Red for Reliable H2O2 Assays

  2026-08-28

  Amplex Red combines low-background fluorescence with flexible workflows for hydrogen peroxide detection, peroxidase measurements, and cellular ROS studies. Its greatest value emerges when mitochondrial and tissue assays include controls for carboxylesterase-driven probe conversion.

• METTL16–SENP3–LTF Axis in HCC Ferroptosis

  2026-08-27

  Wang et al. identify a METTL16–SENP3–LTF regulatory axis that links m6A RNA modification, SUMO-dependent protein stability, and iron handling to ferroptosis resistance in hepatocellular carcinoma. The study integrates cellular, organoid, mouse-model, biochemical, and human-sample evidence, providing a mechanistic framework for sensitizing HCC to ferroptosis-based interventions.

• Letrozole in Reliable Cell Assays

  2026-08-27

  This scenario-based guide shows how Letrozole, SKU A1307, can improve experimental consistency in cell viability, proliferation, and cytotoxicity workflows. It covers mechanism, DMSO compatibility, dose-response design, data interpretation, and practical criteria for selecting a reliable research reagent.

• Catalpol Activates Sirt6–ERα–FasL in Osteoporosis

  2026-08-26

  The reference study identifies a mechanistic link between Catalpol and osteoclast apoptosis in estrogen-deficiency osteoporosis. Using ovariectomized rats and RANKL-induced RAW 264.7 osteoclasts, the authors show that Catalpol promotes Sirt6-dependent ERα deacetylation, stabilizes ERα, and increases FasL-mediated apoptotic signaling.

• Epalrestat: From Polyol Flux to Nrf2 Assays

  2026-08-26

  Epalrestat is an aldose reductase inhibitor that connects polyol pathway inhibition with oxidative stress research. This article presents a mechanism-focused framework for selecting assays, interpreting KEAP1/Nrf2 findings, and translating evidence from diabetic neuropathy research into Parkinson’s disease models.

• α7nAChR Pyroptosis in HIV-1 BBB Breakdown

  2026-08-25

  The reference study identifies brain endothelial pyroptosis as a direct mechanism by which HIV-1 gp120 compromises blood–brain barrier integrity. It positions the α7nAChR/ROS/NF-κB/NLRP3 pathway as a targetable axis and reports that memantine and metformin can suppress this injury in experimental models.

• Sulfaphenazole Restores Vasodilation in Diabetic Mice

  2026-08-25

  The reference study identified CYP 2C-derived reactive oxygen species as a reversible contributor to endothelial dysfunction in db/db mice. Sulfaphenazole restored acetylcholine-mediated vasodilation while lowering oxidative stress and increasing nitric oxide bioavailability without changing plasma glucose, supporting a mechanistic link between cytochrome P450 activity and diabetic vascular injury.

• Abiraterone acetate in 3D Prostate Cancer Research

  2026-08-24

  Build a translational workflow that combines Abiraterone acetate with patient-derived prostate cancer spheroids, controlled exposure chemistry, and orthogonal androgen-response readouts. The approach helps distinguish CYP17 pathway effects from model-specific resistance, compound-access limitations, and direct androgen receptor activity inhibition.

• BKT140 (BL-8040) CXCR4 Research Workflows

  2026-08-24

  BKT140, also known as BL-8040, turns CXCR4 biology into measurable assays for chemotaxis, apoptosis, tumor microenvironment signaling, and stem cell mobilization. This workflow-led guide shows how to formulate the compound, select orthogonal readouts, and troubleshoot results across cancer and hematopoietic models.

• Protease Inhibitor Cocktail for OXPHOS Assays

  2026-08-23

  Protect intact signaling and mitochondrial proteins during cell and tissue extraction with an EDTA-free, broad-spectrum inhibitor format. This workflow shows how to use the cocktail in Western blotting, co-immunoprecipitation, kinase assays, and mechanistic OXPHOS studies without introducing chelation-related interference.

• Bone Transport, TGF-β1, and Diabetic Ulcer Healing

  2026-08-22

  A 2026 rat study shows that bone transport accelerates ischemic diabetic foot ulcer repair while activating TGF-β1/TGFBR1 signaling, angiogenesis, and osteo-immune responses. Its three-arm design and multi-omics validation provide a useful framework for testing pathway dependence, although the findings remain preclinical and should not be directly generalized to other TGF-β-driven diseases.

• A 83-01 and the Translational TGF-β–YAP1 Question

  2026-08-21

  The LPS/TLR4/YAP1 study in hepatocytes creates a compelling translational question: where does TGF-β signaling fit within niche-driven stemness? This article explains how A 83-01 can serve as a selective ALK-5 inhibitor for dissecting Smad-dependent transcription, EMT, organoid behavior, and liver repair hypotheses without overstating what current evidence proves.

• CA800-PR Targets PR and Golgi Stress in Breast Cancer

  2026-08-20

  The reference study introduces CA800-PR, a water-soluble heptamethine cyanine dye that combines tumor-associated uptake, near-infrared imaging, and antitumor activity in hormone receptor-positive breast cancer models. Its reported mechanism links Golgi fragmentation with selective progesterone receptor suppression, apoptosis, inflammatory signaling, and recruitment of MHC class II-positive, CD80-positive macrophages.

• Endothelial STING Signaling in Doxorubicin Cardiotoxicity

  2026-08-20

  The reference study proposes that cardiac vascular endothelial cells, rather than cardiomyocytes alone, initiate and amplify doxorubicin-induced cardiotoxicity through cGAS–STING activation, NLRP3 inflammasome-mediated pyroptosis, and pathogenic extracellular vesicles. It also identifies leonurine as a direct STING inhibitor that binds Tyr261, offering a mechanistically distinct strategy for interrupting endothelial-to-cardiomyocyte injury signaling.

8401 records 1/561 page Next 12345 下5页 Last page